Eyenovia logo
Eyenovia EYEN

Quarterly report 2025-Q2
added 08-13-2025

report update icon

Eyenovia Balance Sheet 2011-2026 | EYEN

Annual Balance Sheet Eyenovia

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-829 K -13.1 M -21.5 M - -27.9 M -14.1 M -19.7 M -5.25 M -3.39 M -2.49 M - - - -

Long Term Debt

718 K 1.29 M 908 K - 366 K - - - - - - - - -

Long Term Debt Current

575 K 501 K 485 K - - - - - - - - - - -

Total Non Current Liabilities

- - - - 404 K 45.4 K 41.6 K - - - - - - -

Total Current Liabilities

16 M 9.53 M 4.51 M 11.2 M 18.2 M 2.91 M 3.1 M 553 K - - - - - -

Total Liabilities

16.8 M 19.8 M 13.8 M 11.2 M 18.6 M 2.96 M 3.14 M 553 K 424 K 420 K - - - -

Retained Earnings

-195 M -145 M -118 M -90.2 M -77.4 M -57.7 M -36.5 M -19.3 M -14.1 M -10.6 M - - - -

Total Assets

3.67 M 28.8 M 31 M 31.7 M 33.9 M 14.7 M 20 M 5.64 M 3.43 M 2.82 M - - - -

Cash and Cash Equivalents

2.12 M 14.8 M 22.9 M 19.5 M 28.4 M 14.2 M 19.7 M 5.25 M 3.39 M - - - - -

Book Value

-13.1 M 9 M 17.2 M 20.5 M 15.3 M 11.7 M 16.9 M 5.09 M 3.01 M 2.4 M - - - -

Total Shareholders Equity

-13.1 M 9 M 17.2 M 20.5 M 15.3 M 11.7 M 16.9 M 5.09 M 3.01 M - - - - -

All numbers in USD currency

Quarterly Balance Sheet Eyenovia

2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

473 K 598 K 718 K 836 K 984 K 1.14 M 1.29 M 1.44 M 1.58 M 1.13 M 908 K - - - - - 7.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

18.3 M 15.7 M 16.8 M 19.1 M 21.4 M 24.4 M 19.8 M 19.1 M 18.8 M 13.5 M 13.8 M 11.1 M 12 M 10.4 M 11.2 M 20.7 M 21.6 M 16.7 M 18.6 M 18.6 M 18.6 M 18.6 M 2.96 M 2.96 M 2.96 M 2.96 M 3.14 M 3.14 M 3.14 M 3.14 M 553 K 553 K - - - - - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

- - - - - - - - - - - - - - - 10 M 10 M 12 M 14 M 14 M 14 M 14 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-207 M -199 M -195 M -175 M -167 M -156 M -145 M -138 M -130 M -124 M -118 M -112 M -105 M -97.6 M -90.2 M -93.2 M -87.6 M -82.8 M -77.4 M -77.4 M -77.4 M -77.4 M -57.7 M -57.7 M -57.7 M -57.7 M -36.5 M -36.5 M -36.5 M -36.5 M -19.3 M -19.3 M -19.3 M -19.3 M -14.1 M - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

55.7 M 5.98 M 3.67 M 22.8 M 19 M 26.2 M 28.8 M 34.9 M 29.3 M 29.3 M 31 M 31.4 M 35.6 M 40.2 M 31.7 M 25 M 30.6 M 28.9 M 33.9 M 33.9 M 33.9 M 33.9 M 14.7 M 14.7 M 14.7 M 14.7 M 20 M 20 M 20 M 20 M 5.64 M 5.64 M 5.64 M 5.64 M 3.43 M - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

7.53 M 3.93 M 2.12 M 7.19 M 2.3 M 7.98 M 14.8 M 20.7 M 17.5 M 18.5 M 22.9 M 17.4 M 21.5 M 26.7 M 19.5 M 13.5 M 27.2 M 24.9 M 28.4 M 28.4 M 28.4 M 28.4 M 14.2 M 14.2 M 14.2 M 14.2 M 19.7 M 19.7 M 19.7 M 19.7 M 5.25 M 5.25 M 5.25 M 5.25 M 3.39 M - - - 2.49 M - - - - - - - - - - - - - - - - - - -

Book Value

37.4 M -9.71 M -13.1 M 3.72 M -2.37 M 1.82 M 9 M 15.8 M 10.5 M 15.8 M 17.2 M 20.3 M 23.6 M 29.8 M 20.5 M 4.25 M 8.99 M 12.1 M 15.3 M 15.3 M 15.3 M 15.3 M 11.7 M 11.7 M 11.7 M 11.7 M 16.9 M 16.9 M 16.9 M 16.9 M 5.09 M 5.09 M 5.64 M 5.64 M 3.43 M - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

37.4 M -9.71 M -13.1 M 3.72 M -2.37 M 1.82 M 9 M 15.8 M 10.5 M 15.8 M 17.2 M 20.3 M 23.6 M 29.8 M 20.5 M 4.25 M 8.99 M 12.1 M 15.3 M 15.3 M 15.3 M 15.3 M 11.7 M 11.7 M 11.7 M 11.7 M 16.9 M 16.9 M 16.9 M 16.9 M 5.09 M 5.09 M 5.09 M 5.09 M 3.01 M - - - 2.4 M - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Eyenovia, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Anika Therapeutics Anika Therapeutics
ANIK
$ 14.93 0.88 % $ 219 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.93 0.51 % $ 5.07 M chinaChina
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.14 0.36 % $ 443 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 8.39 4.5 % $ 230 M israelIsrael
Ardelyx Ardelyx
ARDX
$ 6.06 1.94 % $ 1.46 B usaUSA
argenx SE argenx SE
ARGX
$ 749.68 0.44 % $ 25 B niderlandNiderland
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 23.93 1.27 % $ 3.04 B usaUSA
Arvinas Arvinas
ARVN
$ 11.36 4.7 % $ 805 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 61.99 1.57 % $ 8.29 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Assembly Biosciences Assembly Biosciences
ASMB
$ 29.09 0.28 % $ 326 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Actinium Pharmaceuticals Actinium Pharmaceuticals
ATNM
$ 1.13 15.26 % $ 35.3 M usaUSA
Atossa Therapeutics Atossa Therapeutics
ATOS
$ 5.19 -3.36 % $ 44.7 M usaUSA
Atara Biotherapeutics Atara Biotherapeutics
ATRA
$ 5.0 0.2 % $ 62.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 16.05 2.79 % $ 2.16 B canadaCanada
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.41 -0.35 % $ 375 M britainBritain
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 411.97 -0.2 % $ 31.2 B usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.65 -1.12 % $ 16.6 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
BioCardia BioCardia
BCDA
$ 1.18 -1.67 % $ 7.87 M usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
$ 9.59 6.26 % $ 1.98 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Anavex Life Sciences Corp. Anavex Life Sciences Corp.
AVXL
$ 3.05 1.51 % $ 260 M usaUSA
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$ 9.46 -3.47 % $ 612 M usaUSA
BioVie BioVie
BIVI
$ 1.46 2.81 % $ 2.16 M usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.32 4.98 % $ 908 M israelIsrael
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 56.04 0.96 % $ 10.7 B usaUSA
BioNTech SE BioNTech SE
BNTX
$ 91.64 0.5 % $ 27.2 B germanyGermany
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 1.18 -0.42 % $ 14.4 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 4.5 8.57 % $ 683 M britainBritain